BIOVIE INC. (BIVI) intrinsic value & 10-year financials
BIOVIE INC. (BIVI) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.20
- Market cap
- $1.8M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 177.3%
- Free cash flow (FY2025)
- —
BIVI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$17.5M | -$12.12 | — | — | 561.8% |
| FY2024 | — | -$32.1M | -$7.30 | — | — | 532.4% |
| FY2023 | — | -$50.3M | -$1.55 | — | — | 530.1% |
| FY2022 | — | -$26.1M | -$1.06 | — | — | 175.3% |
| FY2021 | — | -$130.2M | -$7.41 | — | — | 606.6% |
| FY2020 | — | -$16.7M | -$3.42 | — | — | 77.7% |
| FY2019 | — | -$2.4M | -$0.24 | — | — | -218.0% |
| FY2018 | — | -$2.4M | — | — | — | -383.8% |
| FY2017 | — | -$1.3M | — | — | — | -86.6% |
| FY2016 | — | -$431.9K | — | — | — | -22.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BIOVIE INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BIOVIE INC. has historically struggled to out-earn its cost of capital, averaging just -1.3% ROIC.
BIOVIE INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
BIOVIE INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.